A study of host-pathogen responses in tuberculosis elucidates molecular mechanisms of antibiotic tolerance in tuberculosis and further suggests a strategy for shortening curative therapy (currently six months) using a class of drugs — efflux pump inhibitors — that are already approved for treating high blood pressure and angina, and available for use in people.